Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children

Acta Tropica

Volumn 103, Issue 2, 2007, Pages 81-89

  Tahar, Rachida ^a   Basco, Leonardo K ^a  

^a Laboratoire de Recherche sur le Paludisme Yaounde   (Cameroon)

Author keywords

Antifolate drugs; Chloroquine; Drug resistance; Molecular markers; Mutations

Indexed keywords

AMODIAQUINE; ARTEMISININ; ARTESUNATE; CHLOROQUINE; DAPSONE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; SULFONAMIDE;

ALLELE; CHILD HEALTH; COMPARATIVE STUDY; DRUG RESISTANCE; EPIDEMIOLOGY; GENOTYPE; MALARIA; MOLECULAR ANALYSIS; MUTATION; PARASITOLOGY; PROTOZOAN;

ALLELE; ARTICLE; CAMEROON; CHILD; DRUG TREATMENT FAILURE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MOLECULAR EPIDEMIOLOGY; MUTATION; PATIENT MONITORING; PLASMODIUM FALCIPARUM; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ALLELES; ANIMALS; ANTIMALARIALS; CAMEROON; CHILD; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; EPIDEMIOLOGY, MOLECULAR; FOLIC ACID ANTAGONISTS; HUMANS; INFANT; MALARIA, FALCIPARUM; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

AFRICA; CAMEROON; SUB-SAHARAN AFRICA; WEST AFRICA;

PLASMODIUM FALCIPARUM;

EID: 34548048153     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2007.04.008     Document Type: Article

References (44)

1. Aubouy A., Jafari S., Huart V., Migot-Nabias F., Mayombo J., Durand R., Bakary M., Le Bras J., and Deloron P. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J. Antimicrob. Chemother. 52 (2003) 43-49
2. Basco L.K. Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance. Am. J. Trop. Med. Hyg. 69 (2003) 174-178
3. Basco L.K., Eldin de Pécoulas P., Wilson C.M., Le Bras J., and Mazabraud A. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol. 69 (1995) 135-138
4. Basco L.K., Foumane Ngane V., Ndounga M., Same-Ekobo A., Youmba J.C., Okalla R.T., and Soula G. Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine in children before national drug policy change. Am. J. Trop. Med. Hyg. 75 (2006) 388-395
5. Basco L.K., Ndounga M., Keundjian A., and Ringwald P. Molecular epidemiology of malaria in Cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children. Am. J. Trop. Med. Hyg. 66 (2002) 117-123
6. Basco L.K., and Ringwald P. Molecular epidemiology of malaria in Yaoundé Cameroon. II. Baseline frequency of point mutations in the dihydropteroate synthase gene of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 58 (1998) 374-377
7. Basco L.K., and Ringwald P. Molecular epidemiology of malaria in Yaoundé Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am. J. Trop. Med. Hyg. 62 (2000) 271-276
8. Basco L.K., Tahar R., and Escalante A. Molecular epidemiology of malaria in Cameroon XVIII. Polymorphisms of the Plasmodium falciparum merozoite surface antigen-2 gene in isolates from symptomatic patients. Am. J. Trop. Med. Hyg. 70 (2004) 238-244
9. Basco L.K., Tahar R., Keundjian A., and Ringwald P. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J. Infect. Dis. 182 (2000) 624-628
10. Basco L.K., Tahar R., and Ringwald P. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob. Agents Chemother. 42 (1998) 1811-1814
11. Berglez J., Iliades P., Sirawaraporn W., Coloe P., and Macreadie I. Analysis in Escherichia coli of Plasmodium falciparum dihydropteroate synthase (DHPS) alleles implicated in resistance to sulfadoxine. Int. J. Parasitol. 34 (2004) 95-100
12. Brooks D.R., Wang P., Read M., Watkins W.M., Sims P.F.G., and Hyde J.E. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224 (1994) 397-405
13. Bwijo B., Kaneko A., Takechi M., Zungu I.L., Moriyama Y., Lum J.K., Tsukahara T., Mita T., Takahashi N., Bergqvist Y., Björkman A., and Kobayakawa T. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop. 85 (2003) 363-373
14. Dorsey G., Dokomajilar C., Kiggundu M., Staedke S.G., Kamya M.R., and Rosenthal P.J. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am. J. Trop. Med. Hyg. 71 (2004) 758-763
15. Dzinjalamala F.K., Macheso A., Kublin J.G., Taylor T.E., Barnes K.I., Molyneux M.E., Plowe C.V., and Smith P.J. Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 72 (2005) 267-272
16. Foote S.J., Galatas D., and Cowman A.F. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Nat. Acad. Sci. USA 87 (1990) 3014-3017
17. Jelinek T., Kilian A.H.D., Kabagambe G., and Von Sonnenburg F. Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes. Am. J. Trop. Med. Hyg. 61 (1999) 463-466
18. Jelinek T., Ronn A.M., Curtis J., Duraisingh M.T., Lemnge M.M., Mhina J., Bygbjerg I.C., and Warhurst D.C. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance. Trop. Med. Int. Health 2 (1997) 1075-1079
19. Jelinek T., Ronn A.M., Lemnge M.M., Curtis J., Mhina J., Duraisingh M.T., Bygbjerg I.C., and Warhurst D.C. Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. Trop. Med. Int. Health 3 (1998) 605-609
20. Khalil I., Alifrangis M., Ronn A.M., Gabar H.A., Jelinek T., Satti G.M.H., and Bygbjerg I.C. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. Am. J. Trop. Med. Hyg. 67 (2002) 225-229
21. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A.G., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., and Plowe C.V. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis 185 (2002) 380-388
22. Kyabayinze D., Cattamanchi A., Kamya M.R., Rosenthal P.J., and Dorsey G. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am. J. Trop. Med. Hyg. 69 (2003) 247-252
23. Mberu E.K., Nzila A.M., Nduati E., Ross A., Monks S.M., Kokwaro G.O., Watkins W.M., and Sibley C.H. Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance. Exp. Parasitol. 101 (2002) 90-96
24. Mugittu K., Ndejembi M., Malisa A., Lemnge M., Premji Z., Mwita A., Nkya W., Kataraihya J., Abdulla S., Beck H.P., and Mshinda H. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am. J. Trop. Med. Hyg. 71 (2004) 696-702
25. Ndounga M., Basco L.K., and Ringwald P. Evaluation of a new sulfadoxine sensitivity assay in vitro for field isolates of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 55-57
26. Nzila-Mounda A., Mberu E.K., Sibley C.H., Plowe C.V., Winstanley P.A., and Watkins W.M. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42 (1998) 164-169
27. Nzila A.M., Mberu E.K., Sulo J., Dayo H., Winstanley P.A., Sibley C.H., and Watkins W.M. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother. 44 (2000) 991-996
28. Omar S.A., Adagu I.S., and Warhurst D.C. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 315-319
29. Parise M.E., Ayisi J.G., Nahlen B.L., Schultz L.J., Roberts J.M., Misore A., Muga R., Oloo A.J., and Steketee R.W. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am. J. Trop. Med. Hyg. 59 (1998) 813-822
30. Peters W. Chemotherapy and Drug Resistance in Malaria. Second edition (1987), Academic Press, London
31. Peterson D.S., Milhous W.K., and Wellems T.E. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Nat. Acad. Sci. USA 87 (1990) 3018-3022
32. Reeder J.C., Rieckmann K.H., Genton B., Lorry K., Wines B., and Cowman A.F. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am. J. Trop. Med. Hyg. 55 (1996) 209-213
33. Ringwald P., Keundjian A., Same Ekobo A., and Basco L.K. Chimiorésistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part 2: Évaluation de l'efficacité de l'amodiaquine et de l'association sulfadoxine-pyriméthamine pour le traitement de l'accès palustre simple à Plasmodium falciparum à Yaoundé. Cameroun. Trop. Med. Int. Health 5 (2000) 620-627
34. Ringwald P., Same Ekobo A., Keundjian A., Kedy Mangamba D., and Basco L.K. Chimiorésistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part I: Surveillance in vitro et in vivo de la résistance de Plasmodium falciparum à la chloroquine entre 1994 et 1999 à Yaoundé. Cameroun. Trop. Med. Int. Health 5 (2000) 612-619
35. Schultz L.J., Steketee R.W., Macheso A., Kazembe P., Chitsulo L., and Wirima J.J. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am. J. Trop. Med. Hyg. 51 (1994) 515-522
36. Tahar R., and Basco L.K. Molecular epidemiology of malaria in Cameroon XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles. Am. J. Trop. Med. Hyg. 75 (2006) 396-401
37. Talisuna A.O., Nalunkuma-Kazibwe A., Langi P., Mutabingwa T.K., Watkins W.M., Van Marck E., Egwang T.G., and D'Alessandro U. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect. Genet. Evol. 4 (2004) 321-327
38. Terlouw D.J., Courval J.M., Kolczak M.S., Rosenberg O.S., Oloo A.J., Kager P.A., Lal A.A., Nahlen B.L., and ter Kuile F.O. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in western Kenya. J. Infect. Dis. 187 (2003) 467-476
39. Triglia T., Menting J.G.T., Wilson C., and Cowman A.F. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Nat. Acad. Sci. USA 94 (1997) 13944-13949
40. Wang P., Sims P.F.G., and Hyde J.E. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology 115 (1997) 223-230
41. Watkins W.M., Mberu E.K., Winstanley A., and Plowe C.V. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol. Today 13 (1997) 459-463
42. White N.J. The assessment of antimalarial drug efficacy. Trends Parasitol. 18 (2002) 458-464
43. World Health Organization; 1996. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. WHO/MAL/96.1077, World Health Organization, Geneva.
44. World Health Organization; 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HTM/RBM/2003.50, World Health Organization, Geneva.